Home › Funds › Kynam Capital Management, LP › CTMX
Kynam Capital Management, LP position in CTMX
CYTOMX THERAPEUTICS INC. · Health Care
Kynam Capital Management, LP reported holding 21,140,726 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q3 2026 13F filing — a position valued at US$57.5M, representing 3.18% of its reported portfolio and ranking #11 among its reported holdings. Kynam Capital Management, LP has disclosed CTMX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Kynam Capital Management, LP's CTMX position evolved
Kynam Capital Management, LP first disclosed a stake in CTMX in Q2 2025 at 2,154,413 shares (US$4.9M). The position peaked in Q2 2026 at 21,703,093 shares, worth US$81.4M. Across 6 filings, Kynam Capital Management, LP increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 21,140,726 shares valued at US$57.5M — a reduction of -562,367 shares quarter over quarter.. Notable position changes include a 69% increase in Q3 2025 (shares rose 34% over the following quarter), a 146% increase in Q4 2025 (shares rose 10% over the following quarter), a 67% increase in Q1 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 2.15M | $4.89M | New |
| Q3 2025 | 3.65M | $11.63M | Add |
| Q4 2025 | 8.97M | $38.20M | Add |
| Q1 2026 | 15.01M | $70.56M | Add |
| Q2 2026 | 21.70M | $81.39M | Add |
| Q3 2026 | 21.14M | $57.50M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTMX and 13F data
CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 39 other funds we track also report a position in CTMX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$39.1M), Venrock Adviser, LLC (US$18.7M), Elmind Capital, LP (US$17.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTMX
- PERCEPTIVE ADVISORS LLC 10.44M sh · $39.15M · Q2 2026
- Venrock Adviser, LLC 4.98M sh · $18.68M · Q2 2026
- Elmind Capital, LP 4.55M sh · $17.06M · Q2 2026
- Nextech Invest Ltd. 4.45M sh · $16.69M · Q2 2026
- Eversept Partners, LP 3.54M sh · $9.64M · Q3 2026
- Seven Fleet Capital Management LP 1.09M sh · $4.07M · Q2 2026
- Ally Bridge Group (NY) LLC 775.00K sh · $2.91M · Q2 2026
More on Kynam Capital Management, LP
FAQ
How long has Kynam Capital Management, LP held CTMX?
Kynam Capital Management, LP has disclosed CTMX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Kynam Capital Management, LP's current position in CTMX?
As of Q3 2026, Kynam Capital Management, LP holds 21.14M shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $57.50M, representing 3.18% of its reported portfolio and ranking #11.
Has Kynam Capital Management, LP been buying or selling CTMX?
In the latest 13F filing (Q3 2026), Kynam Capital Management, LP reduced its position in CTMX. The position peaked in Q2 2026 at 21.70M shares.
Which other funds hold CTMX?
Other major institutional holders of CTMX include PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, Elmind Capital, LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.